Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.38 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494878 | 1.00 | ADORA2A (0.56) | ADORA2AADORA2BAXLMKNK1MKNK2 | |
| SCHEMBL2881001 | 0.84 | ADORA2A (0.57) | ADORA2AADORA2BAXLMKNK1MKNK2 | |
| SCHEMBL14074698 | 0.82 | ADORA2A (0.60) | ADORA2AADORA2BAXLMKNK1MKNK2 | |
| SCHEMBL27726470 | 0.80 | ADORA2A (0.45) | ADORA2AADORA2BAXLMKNK1MKNK2 | |
| SCHEMBL14074693 | 0.78 | ADORA2A (0.56) | ADORA2AADORA2BAXLMKNK1MKNK2 | |
| SCHEMBL30095652 | 0.76 | ADORA2A (0.54) | ADORA2AADORA2BAXLMKNK1MKNK2 | |
| SCHEMBL28762328 | 0.76 | ADORA2A (0.47) | ADORA2AADORA2BAXLMKNK1MKNK2 | |
| SCHEMBL27726474 | 0.75 | TSHR (0.51) | ADORA2AADORA2BMEN1ALDH1A1MAPT | |
| SCHEMBL18097055 | 0.74 | ADORA2A (0.64) | ADORA2AADORA2BADORA1MEN1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL31745019 | 0.72 | ADORA2A (0.44) | ADORA2AADORA2BAXLMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-2207780-B1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS R&D LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-8354415-B2 | Thienopyrimidine compounds and compositions | VERNALIS (R&D) LTD. (GB) | 2013-01-15 | — | — | US | disclosed |
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R&D) LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2207780-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | Vernalis (R&D) Ltd. (GB) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009037468-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885AXL 1871/4885 |
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ADORA2B, CYP2B6, RRM2B | ADORA2A 51/4885ADORA2B 1/4885AXL 1633/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885AXL 1871/4885 |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885AXL 1871/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | ADORA2A 847/4885ADORA2B 754/4885AXL 1446/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | ADORA2A 671/4885ADORA2B 972/4885AXL 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.